NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Ardent Health, Inc. (NYSE: ARDT) between July 18, 2024 and November 12, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

SAN FRANCISCO, Jan. 9, 2026 /PRNewswire/ -- Hyperscaler development company Fermi Inc. (NASDAQ: FRMI) is facing a proposed securities class action stemming from its highly anticipated initial public offering completed just weeks before stunning the investment community with its December announcement that the prospective anchor tenant ("First Tenant") for the company's Project Matador (the company's Advanced Energy and Intelligence Campus at Texas Tech University) terminated an agreement that would have advanced $150 million to help fund construction. Hagens Berman is investigating the alleged claims that Fermi IPO materials were misleading and urges investors in Fermi who suffered significant losses to …

TAIZHOU, China, Jan. 09, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the “Company”), today announced that it has entered into a definitive agreement with a single investor for the purchase and sale of an aggregate of 66,666,666 Class A ordinary shares of the company, no par value per share (the “Shares”) (or pre-funded warrants in lieu thereof), at a purchase price of $0.15 per share in a registered direct offering. The purchase price for each pre-funded warrant is identical to the purchase price for each Share, less the exercise price of $0.001 per share.

SAN FRANCISCO, Jan. 9, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Ardent Health, Inc. (NYSE: ARDT) following the company's Q3 2025 financial disclosures that revealed significant adverse accounting adjustments totaling about $90 million and sent the stock tumbling over 33% in mid-November. The lawsuit seeks to represent investors who purchased or otherwise acquired Ardent securities between July 18, 2024 and November 12, 2025.

SAN DIEGO, Jan. 9, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that investors in SLM Corporation a/k/a Sallie Mae (NASDAQ: SLM; SLMBP) securities between July 25, 2025 and August 14, 2025, inclusive (the "Class Period"), have until February 17, 2026 to seek appointment as lead plaintiff of the SLM class action lawsuit. Captioned Zappia v.

Shares of Netflix have tumbled since October, when the streaming giant became one of the presumed suitors for Warner Bros. Discovery.

NEW YORK, Jan. 9, 2026 /PRNewswire/ -- S&P Global's (NYSE: SPGI) fourth quarter and full-year 2025 results will be issued on Tuesday, February 10, 2026 via news release at approximately 7:15 a.m. Eastern Time.

Bed Bath & Beyond (BBBY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces an investigation into potential breaches of fiduciary duty by the Board of Directors of Grindr Inc. (NYSE: GRND).

SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Apogee Enterprises, Inc. (NASDAQ: APOG) or certain of its officers and directors may have violated federal securities laws.

SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential derivative claims on behalf of Five Below, Inc. (NASDAQ: FIVE) concerning alleged breaches of fiduciary duty and other violations of state and federal law by certain officers and directors.

Control over Venezuela's oil has been in the spotlight all week, but developments in Iran are key to crude's latest rise.

Revolution Medicines (RVMD) remains a "Strong Buy", driven by advanced RAS [ON] inhibitor programs and robust clinical progress, notably with Daraxonrasib. Company's phase 3 RASolute-302 trial in metastatic PDAC RAS-mutant patients is a major catalyst, with data expected in 2026 and significant expansion potential. Buyout interest from major pharma, including rumored $28–32B bids, underscores RVMD's strategic value and enhances upside optionality.

GAP faces Athleta's prolonged reset, but strong comps at Old Navy raise the question of whether portfolio strength can offset the drag.

Electric vehicle stocks haven't fared well ever since the EV tax credit expired on September 30, 2025.

We are entering a new earnings season. Earnings reports are crucial to understanding a company's outlook for revenue and profit in the coming quarters, especially as headwinds still exist in many sectors of the economy.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE: ARDT) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ARDENT HEALTH, INC. (ARDT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On November 12, 2025, after market hours, Ardent released its third.

JOBY plans to double aircraft output by 2027 after buying a 700,000-square-foot Dayton facility, expanding Ohio operations and near-term capacity.

Jazz Pharmaceuticals plc (JAZZ) Discusses HERIZON-GEA-01 Phase III Trial Results for Zanidatamab in HER2+ GEA Transcript

CNBC's Julia Boorstin reports on Meta's nuclear deals.